|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Our results support a functional role of CXCL3 in breast cancer metastasis and as a viable target for cancer therapy.
|
24605943 |
2014 |
|
Mammary Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Meta-analysis of the mRNA level of CXCL3 in 1881 breast tumors supported a role of CXCL3 in clinical breast cancer.
|
24605943 |
2014 |
|
Malignant neoplasm of breast
|
0.310 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Heart Failure, Diastolic
|
0.300 |
Biomarker
|
disease |
CTD_human |
In Silico Analysis of Differential Gene Expression in Three Common Rat Models of Diastolic Dysfunction.
|
29556499 |
2018 |
|
Dermatologic disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning, Inorganic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Nervous System, Organic Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Encephalopathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Induced Polyneuropathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Mammary Neoplasms, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Mammary Carcinoma, Human
|
0.300 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
KRAS<sup>∗</sup>-mediated repression of IRF2 results in high expression of CXCL3, which binds to CXCR2 on myeloid-derived suppressor cells and promotes their migration to the tumor microenvironment.
|
30905761 |
2019 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Reverse transcription‑quantitative PCR (RT‑qPCR) analysis of 38 paired tumor and non‑tumor tissues, and immunohistochemistry (IHC) of 212 tumor and 46 non‑tumor tissues was conducted to explore the expression of CXCL3 and its diagnostic and prognostic significance in the Guangxi Medical University CC cohort.
|
31545503 |
2019 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Molecular and functional characterization of tumor-induced factor (TIF): Hamster homolog of CXCL3 (GRO<sub>γ</sub>) displays tumor suppressive activity.
|
29276973 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
CCK-8, transwell assays and growth of tumor xenografts were conducted to characterize the effects of CXCL3 on PC-3 cells' proliferation and migration.
|
29524043 |
2018 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Expression of GRO-2 and GRO-3 was already enhanced in premalignant adenomas, and GRO-3 was significantly down-regulated in liver metastasis as compared to the primary tumor.
|
20162422 |
2010 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We showed by microarray and by RT-PCR that NDRG3 overexpression up-regulates the expression of many angiogenic chemokines including CXCL1 (chemokine ligand 1), CXCL3 (chemokine ligand 3) and CXCL5 (chemokine ligand 5), which may increase angiogenesis of tumors.
|
18975380 |
2009 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 belongs to the CXC-type chemokine family and is known to play a multifaceted role in various human malignancies.
|
31667838 |
2020 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that CXCL3 autocrine/paracrine pathways are involved in the development of prostate cancer by regulating the expression of the target genes that are related to the progression of malignancies.
|
29524043 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 was reportedly associated with the invasion and metastasis of various malignancies, the role of CXCL3, however, in preeclampsia has not been fully discussed.
|
29884302 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CXCL3 and its receptor CXCR2 were considered to play particularly important roles in the progression of malignancies.
|
26837773 |
2016 |